Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With the recent payer wins in hand, positive feedback from sleep specialists and people with narcolepsy, growing momentum and product fulfillment, and strong execution from our team, we believe we are well positioned for long term LUMRYZ growth and ultimately for LUMRYZ to become the preferred oxybate for people with narcolepsy and HCPs |
| In addition to the unmatched achievement of launching LUMRYZ within approximately one month of final FDA approval, since launch last June LUMRYZ has seen strong uptake among patients and prescribers, which has been supported by the positive feedback we've received from the broader narcolepsy community |
| So -- and what we see internally is some strong early signs that people are going beyond where twice nightly oxybates were being used previously -- previous to LUMRYZ being in the marketplace |
| Our team's nearly decade long dedication to advancing LUMRYZ and to the sleep medicine space overall has allowed us to build a foundation for continued growth and the potential expansion of LUMRYZ |
| But the team has done an excellent job to kind of ramp that up relatively quickly since the back end of last year, and we'll have more to talk about in the near future, for sure |
| We are proud of the momentum we are building and all we have accomplished thus far, and this is evidenced by the $19.5 million in LUMRYZ net revenue in the fourth quarter and the $28 million for the seven months ended December 31, 2023 |
| And we believe we're well positioned today and also as new therapies come out in the future as well |
| We believe approval in the pediatric population will allow LUMRYZ to provide further positive impact to the narcolepsy community and caregivers at large |
| So, we believe that LUMRYZ is well positioned not only in NT2, but clearly because of the benefit that it has in NT1 as well |
| And we're seeing obviously strong penetration within existing oxybate prescribers |
| In closing, we ended this year in a strong position with a healthy balance sheet to support our operations and our continued growth |
| Coupled with the progress already made this year, we believe we're well positioned to expand our reach and impact within the sleep medicine space and, most importantly, continue executing the launch of LUMRYZ |
| I am proud of the significant accomplishments and progress our team has delivered over the past year and remain highly confident that we will continue that during the year ahead |
| We believe we are well positioned to advance LUMRYZ to command a meaningful share of the multibillion dollar oxybate market and maintain our view that LUMRYZ offers a greater than $1 billion potential market opportunity |
| So -- and generally what we have seen is a pretty good success rate oftentimes after many rounds of appeals and denials going through where we still can get a large portion of these patients initiated onto reimbursed therapy as well |
| And the reception and the turnout has been really positive to, sort of, see that many sort of sleep specialists that have come out to these programs |
| Now taking a step back and looking at what we achieved this past year, we are so proud to be part of a team that has been able to bring a life changing treatment to the narcolepsy community |
| And we're clearly very pleased to sort of see strong demand coming in through RYZUP as well |
| And we think it's another meaningful upside for the long term value of LUMRYZ, for sure |
| Since that time, we've continued to see strong demand with now greater than 2,200 patient enrollments through the end of January |
| We're really pleased where we sit, and certainly we believe are beating the benchmark relative to the existing therapies in the marketplace |
| We are seeing our overall conversion rate start to increase over time here as well, so -- and we're seeing both an improvement in the time, especially with patients who are covered with -- who meet the PA criteria |
| We're very pleased to sort of see the penetration that we've had |
| For product fulfillment, we continue to make strong progress demonstrated by the greater than 1,200 patients who have initiated therapy as of January 31st |
| With the strong foundation our team has built and the tenacity in bringing LUMRYZ to the narcolepsy community, we are pleased to see the momentum we created last year has continued as we've entered 2024 |
| In February, we saw continued improvement in progress with our trends |
| First, I think, when it -- as it relates to conversions and discontinuation rates, I think, with two full quarters into the launch, I think we've done incredibly well in both conversion to initiating on therapy and how we've effectively managed the discontinuation rates through all of our programs and services |
| Greg touched on this earlier, but our LUMRYZ commercial results continue to be strong since we launched last June, and we remain laser focused on keeping the momentum growing in 2024 |
| So, yes, we're very pleased with what the team has been doing through RYZUP and our field reimbursement team for conversion |
| So, is it still fair to assume that most or the large majority of these sign-ups are bound to convert, suggesting discontinuation rates should still remain very favorable, maybe directionally well below 25%? And, secondly, you're on a great trajectory with the strong monthly adds, the healthy conversion rates |
| Statement |
|---|
| And here's the one thing that's also a little bit challenging right now |
| But along with that, to your point, our discontinuation rate is below what we've seen historically for the twice nightly oxybates |
| So, we are seeing our rate of discontinuation rates below the historical twice nightly claims historically |
| We have heard directly from parents about the challenges associated with the middle of the night dosing and the burden a twice nightly dosing regimen may create for the entire family |
| And as I try to square your commentary and your ramp with Jazz's guidance, it seems like market growth must be an important variable there |
| We believe that net cash used for operations will be materially lower after taking into account expected cash receipts from continuing sales of LUMRYZ |
| No problem |
| They say you're not growing the market that much yet |
| So, obviously, the trajectory cannot last forever |
| It's hard for them to wake up |
Please consider a small donation if you think this website provides you with relevant information